×
About 25,578 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  7,158 results

Commentary: Conditions Associated with AD, August 2022
https://www.mdedge.com/dermatology/article/256875/atopic-dermatitis/commentary-conditions-associated-ad-august-2022
Jonathan Silverberg, MD, PhD, MPH

Aug 8th, 2022 - Jonathan Silverberg, MD, PhD, MPH Atopic dermatitis (AD) is truly a fascinating disease! Despite the thousands of scientific manuscripts published on AD, more novel insights keep coming about the clinical manifestations and risk factors of this co.

The prenatal and postnatal effects of air pollution on asthma in children with atopic d...
https://doi.org/10.1002/ppul.26089
Pediatric Pulmonology; Chen IL, Chung HW et. al.

Aug 6th, 2022 - Air pollution is strongly associated with asthma, but has not been determined to induce new-onset asthma development in children with atopic dermatitis (AD). To assess whether prenatal/postnatal exposure to air pollutants triggers new-onset asthma...

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05117060

Aug 5th, 2022 - This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it works to treat AD and what the side effects are when compared ...

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05155085

Aug 5th, 2022 - This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately...

Therapeutic delivery: industry update covering January 2022.
https://doi.org/10.4155/tde-2022-0032
Therapeutic Delivery; Simpson I

Aug 5th, 2022 - This industry update covers the period from January 1 through January 31, 2022, and is based on information sourced from company press releases, scientific literature, patents and news websites. January 2022 saw Janssen and Midatech expand their c...

see more →

Guidelines  9 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  498 results see all →

Clinicaltrials.gov  1,043 results

Natural History of Severe Allergic Inflammation and Reactions
https://clinicaltrials.gov/ct2/show/NCT01164241

Aug 5th, 2022 - Allergic inflammation is central to the pathogenesis of allergic diseases, including atopic dermatitis, asthma, allergic rhinitis, and food allergy. These disorders are common, affecting up to 50 million Americans, and their pathophysiology remain...

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05117060

Aug 5th, 2022 - This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it works to treat AD and what the side effects are when compared ...

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05155085

Aug 5th, 2022 - This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately...

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03916081

Aug 4th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream 0.05% or ARQ-151 cream 0.15% or vehicle is applied QD x 4 weeks to adolescent and adult subjects with atopic dermatitis. A subset of subjects will have serial ...

see more →

News  1,509 results

Commentary: Conditions Associated with AD, August 2022
https://www.mdedge.com/dermatology/article/256875/atopic-dermatitis/commentary-conditions-associated-ad-august-2022
Jonathan Silverberg, MD, PhD, MPH

Aug 8th, 2022 - Jonathan Silverberg, MD, PhD, MPH Atopic dermatitis (AD) is truly a fascinating disease! Despite the thousands of scientific manuscripts published on AD, more novel insights keep coming about the clinical manifestations and risk factors of this co.

Dermatologists Share Vitiligo Breakthrough News With Patients
https://www.medscape.com/viewarticle/978705

Aug 5th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a US Food and Drug Administration (FDA)-approved, easy-to-use to...

Topical Ruxolitinib Quickly Relieves Atopic Dermatitis Itch in Black Patients
https://www.medscape.com/viewarticle/978653

Aug 4th, 2022 - Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream monotherapy over 8 weeks was associated with rapid and c...

Cultural humility required to optimize treatment of eczema patients with skin of color
https://www.mdedge.com/dermatology/article/256788/atopic-dermatitis/cultural-humility-required-optimize-treatment-eczema
Doug Brunk

Aug 3rd, 2022 - INDIANAPOLIS – Treating atopic dermatitis (AD) in children and adolescents with skin of color requires an acumen that extends well beyond the skin, said Candrice R. Heath, MD, at the annual meeting of the Society for Pediatric Dermatology.

Atopic dermatitis and infectious cutaneous disorders: What is the link?
https://www.mdedge.com/dermatology/article/256553/atopic-dermatitis/atopic-dermatitis-and-infectious-cutaneous-disorders

Jul 27th, 2022 - Key clinical point: Risk for cutaneous infectious diseases is significantly higher in adults and children with atopic dermatitis (AD) than individuals without AD, with the risk for molluscum contagiosum being the highest. Major finding: Patients w.

see more →

Patient Education  14 results see all →